# Safety and Efficacy Study of MBX-102 in Treatment of Hyperuricemia in Patients With Gout

> **NCT01336686** · PHASE2 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 67 (actual)

## Conditions studied

- Hyperuricemia
- Gout

## Interventions

- **DRUG:** Arhalofenate
- **DRUG:** Arhalofenate
- **DRUG:** Placebo comparator
- **DRUG:** Colchicine

## Key facts

- **NCT ID:** NCT01336686
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-05
- **Primary completion:** 2011-11
- **Final completion:** 2011-11
- **Target enrollment:** 67 (ACTUAL)
- **Last updated:** 2015-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01336686

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01336686, "Safety and Efficacy Study of MBX-102 in Treatment of Hyperuricemia in Patients With Gout". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01336686. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*